Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)

British Journal of Cancer

Volumn 86, Issue 3, 2002, Pages 456-462

  Sewell, J M ^a   Macleod, K G ^a   Ritchie, A ^a   Smyth, J F ^a   Langdon, S P ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

EGF receptor; Iressa; Ovarian cancer; Tyrosine kinase inhibitor; ZD 1839

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL DIVISION; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0036473508     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600058     Document Type: Article

References (26)

1. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
2. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
3. Epidermal growth factor-receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer
4. Receptors for epidermal growth factor and other polypeptide mitogens
5. Requirements for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor
6. Epidermal growth factor-mediated cell motility: Phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement
7. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
8. Mitogenic effects of epidermal growth factor and transforming growth factor-α on EGF-receptor positive human ovarian cancer cell lines
9. The pathway of signal achievement
10. Phase I trial of chimerized anti-epidermal growth factor receptor (anti-EGFr) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies
11. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
12. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
13. Inhibition of the epidermal growth factor tyrosine kinase by PD 153035 in human A431 tumors in nude mice
14. Characterization and properties of nine human ovarian adenocarcinoma cell lines
15. Tyrosine kinase inhibition: An approach to drug development
16. A phase I study of chimerized anti-epidermal growth factor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC)
17. Evidence for the involvement of transforming growth factor α and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro
18. The erbB signaling network: Receptor dimerization in development and cancer
19. Estrogen regulation of transforming growth factor-α in ovarian cancer
20. Inhibition of transforming growth factor-α TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868
21. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase
22. Transforming growth factor-alpha acts as an autocrine growth factor in ovarian carcinoma cell lines
23. UKCCCR Guidelines for the welfare of animals in experimental neoplasia
24. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts
25. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
26. ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development